// App-Quantinova.ai

4689 : Successfully targeting triple negative breast cancer using combination therapy of Didox and Doxorubicin with reduced cardiotoxicity

Researchers

Presenter

  • Elizabeth A. Wilson

Principal Investigators

  • Howard L. Elford

  • Jesika S. Faridi

Medical Centers

  • University of the Pacific, Stockton, CA

  • Molecules for Health, Inc., Richmond, VA.

Locations

  • United States

Companies

  • Molecules for Health

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Triple-negative breast cancer

  • Cardiotoxicity

  • Breast cancer

  • Solid malignancies

Biomarkers

  • Ribonucleotide reductase subunit M2

Drug/Treatment

  • Doxorubicin

  • Didox

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved